Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis

Pal, Ajay ; Gupta, Swati ; Jaiswal, Anil ; Dube, Anuradha ; Vyas, Suresh P. (2012) Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis Journal of Liposome Research, 22 (1). pp. 62-71. ISSN 0898-2104

Full text not available from this repository.

Official URL: http://www.tandfonline.com/doi/full/10.3109/089821...

Related URL: http://dx.doi.org/10.3109/08982104.2011.592495

Abstract

The antifungal and antileishmanial agent amphotericin B (AmB) was formulated in tripalmitin based nanosize lipid partices (emulsomes) for macrophage targeting for the treatment of visceral leishmaniasis (VL). Emulsomes were modified by coating them with macrophage-specific ligand (O-palmitoyl mannan, OPM). The antileishmanial activity of AmB (0.5 and 1 mg/kg) was investigated in-vivo against VL by the inhibition of parasitic load in the spleen of L. donovani infected hamsters after intraperitoneal injections of AmB-Doc (Mycol), plain emulsomes (TPEs) and OPM coated emulsomes (TPEs-OPM). The formulations were found to be less effective at the dose of 0.5 mg/kg. At the dose of 1 mg/kg, formulation TPEs-OPM eliminated intracellular amastigotes of L. donovani within splenic macrophages more efficiently (62.76 ± 3.54 % parasite inhibition) than the formulation TPEs (42.68 ± 2.36 % parasite inhibition) (P < 0.01) or AmB-Doc (25.87 ± 3.87 % parasite inhibition) (P < 0.001). Our results suggest that these formulations (plain and ligand grafted emulsomes) are a promising substitute to the conventional AmB-Doc formulation for the treatment of VL.

Item Type:Article
Source:Copyright of this article belongs to Taylor & Francis.
Keywords:Macrophage; Targeting; Amphotericin B; O-Palmitoyl Mannan
ID Code:101826
Deposited On:11 Mar 2017 14:57
Last Modified:11 Mar 2017 14:57

Repository Staff Only: item control page